GPL in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
Prospective, open-ended, single-arm, multicenter Phase II clinical trial. To evaluate the
efficacy of Glofitamab, Poseltinib, and Lenalidomide combination therapy in patients with
relapsed/refractory diffuse large B-cell lymphoma.